A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219
Recruiting
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/17/2025
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +57 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
NCT06623396
Recruiting
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
Register for Updates
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
NCT06645886
Recruiting
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of California, San Francisco (UCSF), San Francisco, California +17 locations
Conditions: Hematologic Malignancies, Adult
Register for Updates
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394
Recruiting
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053), Greenville, South Carolina +3 locations
Conditions: Breast Neoplasms, Breast Cancer
Register for Updates
Sleeper Stretch in CrossFit Participants
NCT06720155
Recruiting
The purpose of this study is to compare the efficacy of the sleeper stretch in improving shoulder range of motion, strength and upper body performance in CrossFit athletes.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/17/2025
Locations: Mayo Clinic Health System-La Crosse, La Crosse, Wisconsin +1 locations
Conditions: Shoulder Pain
Register for Updates
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds
NCT06787690
Recruiting
The goal of this study is to look at clinical outcomes when Cohealyx Collagen Matrix is used to treat full thickness wounds after surgical excision in patients that require a skin graft to heal their wounds. The main question it aims to answer is how long does it take for Cohealyx to support definitive closure.
Gender:
ALL
Ages:
All
Trial Updated:
04/17/2025
Locations: University of South Alabama, Mobile, Alabama +9 locations
Conditions: Burn, Trauma Wound, Full Thickness Wounds, Surgical Wound
Register for Updates
Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients
NCT06824402
Recruiting
The goal of this clinical trial is to evaluate which biopsy collection method helps to better diagnose rejection and relevant pathologic findings in lung transplant recipients. The main questions it aims to answer are: Does the 1.1 mm cryoprobe or the biopsy forceps provide better quality samples of lung tissue for detecting rejection in transplant recipients? How much tissue is adequate for lung transplant 1.1 mm cryobiopsy samples as compared to biopsy forceps? Which samples received by the... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/17/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Lung Transplant Rejection
Register for Updates
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
NCT06890611
Recruiting
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/17/2025
Locations: Fortrea Clinical Research Unit, Dallas, Texas
Conditions: Healthy
Register for Updates
Traumatic Hemothorax Drainage and Daily Lavage: Pilot Study
NCT06937450
Recruiting
This HTX treatment study evaluates the effects of chest tube size and the benefits of daily irrigations on acute HTX. 20 acutely injured but stable trauma patients requiring a chest tube for HTX will be enrolled. Patients will be assigned a 28Fr or 14 Fr chest tube with serial lavage and drainage. The endpoints will be HTX volume (by CT scan), complications, additional interventions, hospital length of stay, chest tube duration, provider feedback, and patient-reported outcomes.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/17/2025
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Hemothorax; Traumatic
Register for Updates
Characterization of Diseases With Salivary Gland Involvement
NCT02327884
Recruiting
Background: - Salivary glands in and around the mouth and throat make saliva. Salivary gland disorders can affect a person s quality of life. Studying people who have a disease that affects their salivary gland(s) may teach researchers about the disorders and their genetics. Objectives: - To study salivary gland diseases and disorders. To collect data and samples from people with salivary gland problems and their relatives. Eligibility: * People more than 4 years old who have or are suspect... Read More
Gender:
ALL
Ages:
Between 4 years and 100 years
Trial Updated:
04/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer, Salivary Gland Disease, Sjogren's Syndrome
Register for Updates
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
NCT03458832
Recruiting
The primary cause of facioscapulohumeral muscular dystrophy (FSHD), a common adult-onset dystrophy, was recently discovered identifying targets for therapy. As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hasten drug development, including creating disease-relevant outcome measures and optimizing inclusion criteria. This proposal will develop two new outcome measures (FSHD-COM and EIM) and optimize eligibility crit... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: University of California Los Angeles, Los Angeles, California +13 locations
Conditions: Facioscapulohumeral Muscular Dystrophy
Register for Updates
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03821935
Recruiting
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Highlands Oncology Group, PA /ID# 218942, Springdale, Arkansas +63 locations
Conditions: Advanced Solid Tumors Cancer
Register for Updates